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ABSTRACT
Background
Tuberculosis, which is caused by Mycobacterium tuberculosis, remains one of the leading
causes of mortality worldwide. The C-type lectin DC-SIGN is known to be the major M.
tuberculosis receptor on human dendritic cells. We reasoned that if DC-SIGN interacts with M.
tuberculosis, as well as with other pathogens, variation in this gene might have a broad range of
influence in the pathogenesis of a number of infectious diseases, including tuberculosis.
Methods and Findings
We tested whether polymorphisms in CD209, the gene encoding DC-SIGN, are associated
with susceptibility to tuberculosis through sequencing and genotyping analyses in a South
African cohort. After exclusion of significant population stratification in our cohort, we
observed an association between two CD209 promoter variants ( 871G and  336A) and
decreased risk of developing tuberculosis. By looking at the geographical distribution of these
variants, we observed that their allelic combination is mainly confined to Eurasian populations.
Conclusions
Our observations suggest that the two 871G and 336A variants confer protection against
tuberculosis. In addition, the geographic distribution of these two alleles, together with their
phylogenetic status, suggest that they may have increased in frequency in non-African
populations as a result of host genetic adaptation to a longer history of exposure to
tuberculosis. Further characterization of the biological consequences of DC-SIGN variation in
tuberculosis will be crucial to better appreciate the role of this lectin in interactions between
the host immune system and the tubercle bacillus as well as other pathogens.
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One-third of the world’s population is estimated to be
infected with Mycobacterium tuberculosis, the etiological agent of
tuberculosis (TB). This disease tops the World Health
Organization list of deaths due to a single infectious agent,
with the death toll between 2 and 3 million people per year [1].
A perplexing, and yet unsolved, feature of TB is that less than
10% of infected individuals develop the disease. Substantial
epidemiological evidence supports that host-related factors,
such as sex, age, HIV infection, malnutrition, and BCG (bacille
Calmette-Gue ´rin) vaccination, inﬂuence the balance between
the tubercle bacilli and host immune defences [2,3]. In
addition, there is increasing evidence that host genetic factors
determine differences in host susceptibility to mycobacterial
infection and might contribute therefore to the pattern of
clinical disease [4–7]. From a host perspective, the innate
immunity system acts as the ﬁrst line of host defense against
microbial pathogens [8]. Initial recognition of pathogens by
the innate immunity system is mediated by phagocytic cells,
such as dendritic cells (DCs) or macrophages, through germ-
line-encoded receptors, known as pattern recognition recep-
tors [9]. DCs bear a range of pattern recognition receptors,
such as C-type lectins and Toll-like receptors, involved both in
recognition of conserved products of microbial metabolism
and in the induction of adaptive immunity [8,10–12]. In
particular, C-type lectins detect pathogens by their character-
istic carbohydrate structures and internalise them for further
antigen processing and presentation [13]. We have recently
shown that a prototypic C-type lectin, DC-SIGN (dendritic
cell–speciﬁc ICAM-3 grabbing nonintegrin), is the major
Mycobacterium tuberculosis receptor on human DCs [14]. DC-
SIGN is speciﬁcally, though not exclusively, expressed on DCs
and functions both as a cell adhesion and as a pathogen
recognition receptor [15]. As an adhesion receptor, it plays an
important role in many DC functions, such as DC-T cell
interaction and DC migration [16,17]. Besides its cellular
recognition role, DC-SIGN serves as pathogen uptake recep-
tor and mediates interactions with a plethora of pathogens
other than M. tuberculosis [18]. Indeed, it has been shown that
DC-SIGN allows DCs to capture other bacteria such as
Helicobacter pylori and certain Klebsiella pneumonia strains, but
also viruses such as HIV-1, Ebola, cytomegalovirus, hepatitis-
C, dengue, and SARS-coV, and parasites like Leishmania pifanoi
and Schistosoma mansoni [19–27]. In addition, recent data
suggest that DC-SIGN may mediate intracellular signalling
events leading to cytokine secretion and, on this basis, it has
been proposed that the lectin could be used by pathogens,
including M. tuberculosis, as a part of an immune evasion
strategy to their own advantage [28,29].
In light of the ability of DC-SIGN to interact with M.
tuberculosis and other pathogens, it is plausible that variation
in its gene may inﬂuence the pathogenesis of a number of
infectious diseases, including TB. We have therefore explored
the relationship between CD209 polymorphisms and suscept-
ibility to TB by determining CD209 sequence variation in a
cohort of South African Coloured origin.
Methods
Patients and Methods
The study was conducted in a cohort of 711 individuals,
including 351 TB patients and 360 healthy controls, living in
the Cape Town area. Certain suburbs of metropolitan Cape
Town have some of the highest reported incidence rates of TB
in the world, despite extensive BCG vaccination. Indeed, our
study population comes from two suburbs that have been
extensively studied because of their uniform ethnicity (known
as South African Coloured) and socio-economic status as well
as high incidence of TB and low prevalence of HIV [30]. In
addition, our study group represents a present-day homoge-
nous population [31] that previously received genetic input
from Khoisan, Malaysian, Bantu, and European descent
populations [32]. Thus, it represents a community originating
from populations with different susceptibilities to TB and
offers a unique opportunity to dissect the contributing
genetic variants and their probable geographic/ethnic origins.
TB patients were bacteriologically-conﬁrmed (smear-positive
and/or culture-positive) to present pulmonary tuberculosis.
Their mean age (6 standard deviation) was 36.7 6 10.9 y, and
51.8% were male. Controls were unrelated healthy individuals
from the same community, with the same socio-economic
status, access to health facilities, and chance of diagnosis, and
with neither signs nor previous history of TB (mean age 34.6 6
12.5 y, 22% male). The annual risk of infection in this suburb
was estimated at 2.5% in 1987 and at 2.8%–3.5% in 1999, and
it is therefore highly likely that, in such an environment, the
vast majority of controls have been exposed to M. tuberculosis
[33,34]. All subjects were HIV-negative and older than 18 y.
Informed consent was obtained from all participants, and the
study was approved by the ethics committee of the Faculty of
Health Sciences, Stellenbosch University (South Africa).
Laboratory Procedures and Statistical Analysis
To identify informative CD209 single nucleotide poly-
morphisms (SNPs) and to avoid ascertainment bias in the
choice of markers to be tested, we ﬁrst sequenced the whole
CD209 genomic region (seven coding exons, ﬂanking intronic
regions, and 1,000 base pairs situated 59 of the start codon) in
28 randomly chosen individuals (56 chromosomes). Using
polymorphisms with a minimum allele frequency of 0.05,
unphased genotypic data were converted into haplotypes
using the accelerated EM (Expectation Maximization) algo-
rithm implemented in Haploview v3.1 [35]. To evaluate the
accuracy of the EM algorithm, haplotype reconstruction was
performed in parallel using the Bayesian statistical method
[36] implemented in Phase v.2.1.1. Equivalent results were
obtained using both methods, with all haplotypes presenting
high levels of statistical support. In order to deﬁne a minimal
number of SNPs explaining most haplotypic diversity, we
used the BEST v1.0 software [37]. Eight haplotype-tagging
SNPs were then selected to genotype the entire panel of 711
individuals. Further, potential population stratiﬁcation be-
tween cases and controls was tested by genotyping 25
unlinked SNP markers in the entire study cohort. DNA
samples were genotyped by either ﬂuorescence polarization
(VICTOR-2TM technology; PerkinElmer, Wellesley, Califor-
nia, United States) or TaqMan (ABI Prism-7000 Sequence
Detection System; Applied Biosystems, Foster City, Califor-
nia, United States) assays. Statistical testing for genotypic and
haplotypic associations were performed using STATA 8.2 and
Haploview v3.1, respectively. The haplotype frequencies were
obtained by summing the fractional likelihood of each
haplotype for each individual (i.e., if a particular individual
has been determined to have a 40% likelihood of haplotype A
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added to the counts for A and B, respectively) [35].
Results and Discussion
Two variants located in the CD209 promoter region ( 871
A/G and  336 A/G) exhibited a frequency distribution
signiﬁcantly distorted between TB patients and controls, as
indicated by a Chi-square test (Table 1). For the 871 variant,
genotypes GG and GA were less frequently observed in cases
(16.8%) compared to the control group (27.2%) (p ¼ 8.2 3
10
 4). For the 336 variant, genotypes GG and GA were more
frequent in cases (70.6%) than in controls (61.9%) (p ¼ 0.01).
These observations suggest that the alleles  871A (odds ratio
[OR]: 1.85; 95% CI: 1.29–2.66) and  336G (OR: 1.48; 95% CI:
1.08–2.02) increase the risk of developing TB in our South
African cohort. At the haplotype level (Table 2), a Chi-square
test ﬁrst revealed that the global distribution of haplotype
frequencies was signiﬁcantly different between cases and
controls (p¼1.2310
 3). One haplotype (H3) turned out to be
the main haplotype responsible for such a distorted fre-
quency distribution (Table 2). This haplotype, which contains
both  871G and  336A, was found to be strongly associated
with the control group (p¼1.6310
 3; OR: 1.7; 95% CI: 1.22–
2.38). The associations with this haplotype, and with  871,
remained highly signiﬁcant (p ¼ 1.3 3 10
 2 and 6.6 3 10
 3
respectively), even after the conservative Bonferroni correc-
tion for multiple testing.
Although our cohort is considered a present-day homoge-
neous community that has received genetic contribution
from different populations multiple generations ago [31,32],
population stratiﬁcation between cases and controls can be a
confounding factor leading to a spurious positive association.
Indeed, the use of admixed populations in association-
mapping studies can be very useful to identify disease-causing
genetic variants that differ in frequency across parental
populations. However, when the admixture event is too
recent, allelic frequencies can differ coincidentally among
cases and controls, reﬂecting a nonuniform genetic contri-
bution from the parental populations to each subpopulation
(i.e., cases and controls), rather than a genuine association
between a given genetic variant and the phenotype under
study. In this case, the study-cohort is said to present
population stratiﬁcation. To formally test and quantify the
levels of background genetic differences [38], if any, between
cases and controls, we genotyped the entire cohort for a
panel of 25 independent SNPs markers which are (1) not in
linkage disequilibrium with the candidate CD209 locus and
with any other known gene, (2) randomly distributed along
the genome, and (3) polymorphic among the major ethnic
groups (Table 3). The mean v
2 statistic among the 25 SNPs for
the comparison of allele frequencies between cases and
controls, which represents the levels of stratiﬁcation (l)
between the two groups [39], was 1.25 (p¼0.26), implying that
the two groups were not signiﬁcantly stratiﬁed. As an
additional correction for stratiﬁcation, we divided the v
2
values obtained for our candidate gene CD209 by the level of
stratiﬁcation detected (1.25) [39]. Even after such a con-
servative correction, the associations observed with 336 and
 871 as well as with H3 remained signiﬁcant ( 336 p ¼ 2.8 3
10
 2;  871 p ¼ 2.7 3 10
 3;H 3p ¼ 4.8 3 10
 3). These
observations support therefore the idea that the  871G and
 336A variants are indeed genuinely associated with a
protective role against TB.
In order to gain insights into the frequency distribution of
these two SNPs, we genotyped them in 254 human chromo-
somes from sub-Saharan Africa, Europe, and East Asia as well
as in eight chimpanzee chromosomes. We observed that the
 871G and  336A forms, which we propose as offering
protection against TB, corresponded to the derived allele in
humans; we also observed that these forms are present at
higher frequencies in Eurasians as compared to Africans
(Table 4). Indeed, the 871G is absent in African populations
whereas it reaches high frequencies (20%–40%) in European
and Asian populations. Given the absence of the haplotypic
combination of  871G and  336A among sub-Saharan
Africans, its presence among South African Coloureds
suggests that it was introduced through the historically well-
known admixture with Europeans and Asians [31]. This
observation highlights the power of using admixed popula-
tions to better understand historical issues associated with
the geographic/ethnic origin of disease-affecting alleles,
provided that their prevalence varies in the ancestors of the
admixed population (i.e., different frequency of H3 in
Africans versus non-Africans; Table 4).
In the context of TB, it has been suggested that present-day
Table 1. DC-SIGN Genotype Distributions in Patients with Tuberculosis and in Healthy Controls
Genotype Frequencies (%)
Cases (n ¼ 351) Controls (n ¼ 360) Cases vs. Controls
b
htSNP
a 1 2 11 12 22 11 12 22 p OR
–939 G . A 52.1 39 8.8 45.3 46.9 7.8 0.07 0.76 [0.57–1.02]
–871 A . G 83.2 15.7 1.1 72.8 26.1 1.1 8.2 3 10
 4 1.85 [1.29–2.66]
–336 A . G 29.3 50.4 20.2 38.1 43.3 18.6 0.01 1.48 [1.08–2.02]
–139 A . G 8.3 37.6 54.1 7.2 43.1 49.7 0.24 0.84 [0.62–1.13]
2392 G . A 96.6 3.4 0 95 4.7 0.3 0.29 0.67 [0.32–1.42]
3220 T . C 74.6 23.4 2 75.8 22.8 1.4 0.71 1.07 [0.76–1.50]
3838 A . C 80.1 17.9 2 84.7 14.4 0.8 0.1 1.38 [0.94–2.04]
4235 G . C 51.6 41 7.4 57.2 37.8 5 0.13 1.26 [0.94–1.69]
aAll htSNPs (haplotype tagging SNPs) were in Hardy-Weinberg equilibrium in both the global sample and in cases and controls, separately.
bThe homozygotes for the most frequent allele were compared with the sum of the homozygotes and heterozygotes for the rare allele.
DOI: 10.1371/journal.pmed.0030020.t001
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exposure [40]. There is fairly convincing evidence that TB has
been endemic in Europe for several hundred years, whereas in
Africa it has probably been rare before contact was initiated
with Europeans [41–43]. It is expected therefore that M.
tuberculosis has exerted stronger selective pressures on Euro-
pean than African populations [42]. Our results lend support
to this hypothesis and suggest that the protective alleles
 871G and  336A increased in frequency in non-African
populations as a result of genetic adaptation to a longer
period of TB exposure. The potential impact of tuberculosis
on the frequency of resistant alleles in European populations
has been recently addressed using epidemiological data and
statistical modeling [44]. The authors have sought to evaluate
the expected changes in resistant allele frequencies, during
the 300-y period corresponding to the peak epidemics of TB
in Europe. They concluded that if a given resistant allele was
at a low frequency in the beginning of an epidemic, selection
by M. tuberculosis alone would increase the frequency of this
allele, but not enough to bring it to epidemiologically
signiﬁcant levels. In this context, since DC-SIGN is known to
interact with a vast range of pathogens, it is indeed likely that
Table 2. Haplotype Distributions in Patients with Tuberculosis and in Healthy Controls
Haplotype
a Haplotype Frequencies (%) Cases vs. Controls
b
Cases Controls p OR
H1-AAAGGTCG 10 6.2 0.01 1.70 [1.15–2.52]
H2-AAAGGTAG 7.6 9.3 0.25 0.80 [0.55–1.16]
H3-AGAGGTAG 8.9 14.2 1.6 3 10
 3 1.70 [1.22–2.38]
H4-GAAAGTAG 26 27.9 0.41 0.91 [0.72–1.15]
H5-GAGGGTAG 17.3 15 0.25 1.17 [0.88–1.55]
H6-GAGGGTAC 12.2 8.5 0.02 1.49 [1.05–2.11]
H7-GAGGATAC 1.7 2.2 0.44 0.77 [0.36–1.63]
H8-GAGGGCAC 12.8 11.2 0.35 1.16 [0.84–1.60]
aHaplotypes with frequency greater than 1%. The alleles are ordered from SNP-939 until SNP4235.
bThe frequency of each haplotype in cases and controls was compared with the sum of all the others.
DOI: 10.1371/journal.pmed.0030020.t002
Table 3. Frequency Distribution in the Study Cohort of the 25 SNPs Used to Test for Population Stratification
Name rs Number Location ObsHET
a PredHET
b HWP
c MAF MAF v
2 p-Value
Cases (%) Controls (%)
SNP1 rs2048022 Chr4 0.509 0.497 0.588 43.4 48.3 3.469 0.0625
SNP2 rs1380229 Chr8 0.429 0.468 0.034 36.1 38.4 0.815 0.3667
SNP3 rs650389 Chr10 0.276 0.287 0.369 15.2 19.5 4.518 0.0335
SNP4 rs870384 Chr12 0.511 0.499 0.591 48.3 46.8 0.311 0.5771
SNP5 rs695982 Chr12 0.416 0.419 0.888 32.1 27.7 3.376 0.0662
SNP6 rs708682 Chr15 0.216 0.212 0.826 11.8 12.3 0.086 0.7693
SNP7 rs715774 Chr15 0.244 0.257 0.209 14.3 16.1 0.883 0.3473
SNP8 rs1433456 Chr15 0.313 0.317 0.784 19.9 19.7 0.011 0.9169
SNP9 rs807131 Chr17 0.478 0.453 0.183 35.5 33.9 0.398 0.5279
SNP10 rs11672183 Chr19 0.214 0.209 0.649 12 11.7 0.018 0.8947
SNP11 rs2024628 Chr20 0.513 0.494 0.333 42.2 46.5 2.627 0.1051
SNP12 rs1028184 Chr2 0.461 0.464 0.9 34.2 39 3.53 0.0603
SNP13 rs2056773 Chr3 0.492 0.473 0.32 39.5 37.1 0.808 0.3687
SNP14 rs1479067 Chr5 0.398 0.395 0.972 25.9 28.4 1.099 0.2945
SNP15 rs327747 Chr7 0.374 0.399 0.111 25.8 29.2 2.084 0.1488
SNP16 rs12665321 Chr6 0.239 0.234 0.693 14.2 12.9 0.462 0.4969
SNP17 rs1566838 Chr9 0.475 0.497 0.265 46.5 45.8 0.081 0.7762
SNP18 rs12785524 Chr11 0.452 0.483 0.106 39 42.4 1.708 0.1912
SNP19 rs975423 Chr13 0.429 0.464 0.056 35.1 37.8 1.134 0.2868
SNP20 rs914904 Chr13 0.397 0.409 0.462 29.2 28.2 0.179 0.6723
SNP21 rs876287 Chr14 0.459 0.484 0.182 41.3 40.9 0.024 0.8765
SNP22 rs1582598 Chr16 0.378 0.394 0.321 27.5 26.5 0.164 0.6852
SNP23 rs1364198 Chr16 0.361 0.364 0.908 25.2 22.7 1.242 0.2652
SNP24 rs739259 Chr22 0.469 0.469 1 36.1 39 1.217 0.27
SNP25 rs169479 Chr21 0.217 0.217 1 13.3 11.5 1.064 0.3024
aObserved heterozygosity.
bPredicted heterozygosity.
cHardy–Weinberg equilibrium probability.
MAF, minimum allele frequency.
DOI: 10.1371/journal.pmed.0030020.t003
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 336A in non-African populations (specially for 871G which
is absent in sub-Saharan Africans) may have been driven, not
only by the selective pressures imposed by M. tuberculosis, but
also by other infectious agents. Indeed, two independent
studies have recently reported a genetic association between
the  336A variant and protection against parenteral HIV
infection [45] and severity of dengue pathogenesis [46].
Although HIV infection, for example, is too recent to have
left any signature of selection on CD209, these observations
emphasize the possible action of other pathogens in shaping
the patterns of variability of this gene.
From a functional point of view, the 336A allele has been
shown to affect an Sp1-like binding site and to modulate
transcriptional activity in vitro by increasing the levels of
expression [46]. In the context of TB, increased DC-SIGN
expression levels by DCs may result in better capture and
processing of mycobacterial antigens, leading to a stronger
and wider T-cell response. In addition, we have recently
shown that DC-SIGN expression is markedly induced in
alveolar macrophages in active TB patients and that M.
tuberculosis is preferentially phagocytosed by DC-SIGN–
expressing macrophages in these individuals [47]. Thus, the
higher prevalence observed among healthy individuals of the
 336A variant, which is associated with increased DC-SIGN
expression, may underlie an increased efﬁciency of host
phagocytes, such as DCs and macrophages, to control the
infection. In addition to the  336A variant, our genetic data
showed a strong association of the  871G allele with healthy
controls, suggesting also a functional consequence of this
variant that, either alone or in combination with  336A,
remains to be deﬁned.
In conclusion, the signiﬁcant association found for the
CD209 promoter variants together with their phylogenetic
status and frequency distribution strongly suggests that the
 871Gand 336AallelesmayreducetheriskofdevelopingTB.
More generally, our results, together with those reporting
association of CD209 promoter variants with both HIV
susceptibility and dengue pathogenesis [45,46] suggest that
variation in this lectin may be of crucial importance in the
outcome of a number of infections due to DC-SIGN–interact-
ing pathogens. Detailed in vitro and in vivo studies assessing
the functional consequences of CD209 variants on the quality
of the host immune response against pathogens, including M.
tuberculosis,are now required toeventually develop knowledge-
based and effective pathway-targeted treatments.
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Patient Summary
Background. Tuberculosis (TB) is an infectious disease caused by the
bacterium Mycobacterium tuberculosis. The disease kills between 2
million and 3 million people each year, and almost one-third of the
world’s population, or 2 billion people, are thought to be infected with
the bacterium. However, only about 10% of infected individuals become
sick. In the other cases, the body’s immune system is capable of
controlling the growth of the bacteria. Whether a person’s immune
system is strong enough to keep the bacterium in check depends on a
variety of factors, such as age, how well nourished the person is, other
infections, and genetic make-up.
Why Was This Study Done? Understanding the genetic factors that
influence whether an infected person is more or less susceptible to
getting sick with TB should help doctors to fight the disease. A number
of research groups are studying these genetic factors, and some genes
have previously been identified that seem to increase a person’s risk of
TB. Some of the authors of this study work on a molecule that is part of
the immune system. The molecule is called DC-SIGN, and it plays a role in
infection of cells in the lung by the Mycobacterium. Together with
colleagues who are genetics experts, they wanted to see whether
variation in the gene (called CD209) that codes for DC-SIGN influences
the risk of someone infected with M. tuberculosis getting sick.
What Did the Researchers Do and Find? They worked with a group of
South African participants from an area close to Cape Town where TB is
very common. Half of the participants had TB; the other half did not (even
though,becauseTBissocommoninthatarea,itwaslikelythatmostifnot
all of them had been infected with M. tuberculosis at some point). The
researchers comparedmake-upof the gene for DC-SIGNin all participants
and found that some variants of the gene were more common in the
group of healthy individuals. In other words, having this particular type of
DC-SIGN-encoding gene seemed to protect individuals from getting TB.
What Does This Mean? DC-SIGN is a central part of the immune system,
and others scientists have reported links between variants in the gene for
DC-SIGN and the risk of picking up other infectious diseases, including
dengue fever and HIV/AIDS. The present study lends more support to the
notion that DC-SIGN is a key player in the control of infectious diseases.
Understanding more about DC-SIGN could help to develop better
treatments for these infections.
Where Can I Find More Information Online? The following Web sites
provide information about tuberculosis.
World Health Organization pages on TB:
http://www.who.int/mediacentre/factsheets/fs104/en/index.html
OMNI pages on TB:
http://omni.ac.uk/browse/mesh/D014376.html
Medline PLUS pages on TB:
http://medlineplus.nlm.nih.gov/medlineplus/tuberculosis.html
European TB Vaccine Cluster:
http://www.tb-vac.org
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